The deal is expected to close this quarter, as Advion BioServices will join Quintiles as Advion Bioanalytical Labs, a Quintiles company.
Quintiles Global Laboratories senior vice president Thomas Wollman said the addition of bioanalytical offering to their existing CAP-accredited central labs network would create a one-source solution for lab testing.
"We now can offer customers world-class PK/PD testing, molecular screening, drug discovery and metabolism, biomarker discovery, and immunoassay services to inform decision-making early on, helping reduce the risk of failure in expensive later-stage trials," Wollman added.